NCT05359692 2023-09-15
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Incyte Corporation
Phase 2 Withdrawn
Clinical Trials
4 trialsNCT01075841 2014-07-02
A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck
Merck KGaA, Darmstadt, Germany
Withdrawn
NCT00605709 2012-07-25
Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell Carcinoma
BPGbio
Phase 2 Withdrawn
NCT00233636 2011-01-27
Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
Phase 2 Withdrawn